Lycia Therapeutics, Inc.
No SEC Form 4 filings for $LYCA in the last 30 days.
See all $LYCA insider activity →Lycia Therapeutics (LYCA) closed its upsized IPO, raising about $365 million before expenses. The offering included 20.29 million shares at the IPO price. The company focuses on developing therapeutics to degrade disease-causing proteins, targeting autoimmune and inflammatory diseases.
Over the past 7 days, AlphAI's AI scored 7 news stories mentioning LYCA (Lycia Therapeutics, Inc.). Coverage has skewed bullish: 4 bullish, 2 neutral, and 1 bearish.
Newly listed shares may see buying interest as investors assess the biotech's pipeline.
AlphAI scores every news story that mentions LYCA with an AI model for sentiment and relevance, and aggregates insider trades from Lycia Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Lycia Therapeutics (LYCA) closed its upsized IPO, raising about $365 million before expenses. The offering included 20.29 million shares at the IPO price. The company focuses on developing therapeutics to degrade disease-causing proteins, targeting autoimmune and inflammatory diseases.
2 min read